Global Forecast to 2027 for the Vaccines Market - CAGR of 5.2% Expected During the Forecast Period -

DUBLIN--()--The "Vaccines Market by Indication (Influenza, Rotavirus, DTP Vaccines), Route of Administration (Intramuscular, Subcutaneous, Oral), Type/Antigen (Conjugate Vaccine, Live Attenuated Vaccine), Valence (Multivalent, Monovalent Vaccines) - Global Forecast to 2027" report has been added to's offering.

The global vaccines market is expected to grow at a CAGR of 5.2% from 2019 to 2027 to reach $62.2 billion by 2027.

The growth in the global vaccines market is mainly attributed to the high prevalence of various diseases, increasing government initiatives towards immunization, technological advancements in the vaccine industry, and a strong pipeline for vaccines. In addition, increasing epidemic potentials, growing focus on therapeutic vaccines, and emerging markets will further provide significant opportunities for the various stakeholders in this market. However, longer timelines and high cost for vaccines development are likely to hinder the market growth.

On the basis of indication, the pneumococcal disease segment commanded the largest share of the overall vaccines market in 2019. The large share of this segment is mainly attributed to the factors such as rising incidence of pneumococcal diseases like pneumonia, meningitis, febrile bacteraemia, otitis media, and sinusitis; development of quality vaccines such as PPSV23; and various initiatives by the government organizations and private sectors to prevent and control outbreak of pneumococcal diseases.

On the basis of valence, multivalent vaccines segment accounted for the largest share of the overall vaccines market in 2019 and is poised to grow at a faster CAGR during the forecast period. New product launches and focus of key players on multivalent vaccine' research & development are the major factors contributing to the largest share and fastest CAGR of multivalent vaccines market segment.

On the basis of antigen, subunit and conjugate vaccines segment accounted for the largest share of this market in 2019 due to long term immunity and low-risk rate associated with the subunit vaccines along with the increasing demand for immunization.

Key Topics Covered:

1. Introduction

2 Research Methodology

3. Executive Summary

4. Market insights

4.1. Market Overview

4.2. Drivers

4.2.1. Strong Vaccines Pipeline

4.2.2. Rising Adoption of Vaccination

4.2.3. Increasing Government Focus on Immunization Programs

4.2.4. Technological Progress in Vaccine Administration

4.3. Restraints

4.3.1. High Cost Associated with Vaccine Development

4.3.2. Longer Timelines for Vaccine Manufacturing

4.4. Opportunities

4.4.1. Increasing Epidemic Potentials

4.4.2. Growing Focus on Therapeutic Vaccines

4.4.3. Growth Prospects in Emerging Markets

4.4.4. Increasing Use of Adjuvants in Vaccines

4.5. Challenges

4.5.1. Product Recalls

4.5.2. Inadequate Access to Vaccines

5. Industry Analysis

5.1. Regulatory Analysis

5.2. Pipeline Analysis

5.3. Unmet Needs Analysis

5.4. Pricing Analysis, by Region

6. Global Vaccines Market, by Indication

6.1. Introduction

6.2. Pneumococcal Disease

6.3. Influenza

6.4. Human Papilloma Virus (HPV)

6.5. DTP

6.6. Meningococcal Disease

6.7. MMR

6.8. Rotavirus

6.9. Poliomyelitis (Polio)

6.10. Hepatitis

6.11. Other Indications

7. Global Vaccines Market, by Route of Administration

7.1. Introduction

7.2. Intramuscular (IM)

7.3. Subcutaneous (SC)

7.4. Oral

7.5. Other (Routes of Administration)

8. Global Vaccines Market, by Type/Antigen

8.1. Introduction

8.2. Subunit & Conjugate Vaccines

8.3. Inactivated Vaccines

8.4. Live Attenuated Vaccines

8.5. Toxoid Vaccines

8.6. Combination Vaccines

9. Global Vaccines Market, by Valence

9.1. Introduction

9.2. Multivalent Vaccines

9.3. Monovalent Vaccines

10. Global Vaccines Market, by Geography

10.1. Introduction

10.2. North America

10.2.1. U.S.

10.2.2. Canada

10.3. Europe

10.3.1. Germany

10.3.2. U.K.

10.3.3. France

10.3.4. Italy

10.3.5. Spain

10.3.6. Rest of Europe

10.4. Asia Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Rest of Asia Pacific

10.5. Latin America

10.6. Middle East & Africa

11. Competitive Landscape

11.1. Introduction

11.2. Key Growth Strategies

11.3. Competitive Benchmarking

11.4. Market Share Analysis

11.4.1. Market Share Analysis, by Company

11.4.2. Market Share Analysis, by Product

12. Company Profiles

12.1. Sanofi

12.1.1. Business Overview

12.1.2. Financial Overview

12.1.3. Product Portfolio

12.1.4. Pipeline Products

12.1.5. Strategic Developments

12.2. Merck & Co., Inc.

12.3. GlaxoSmithKline Plc.

12.4. Pfizer, Inc.

12.5. Johnson & Johnson

12.6. Daiichi Sankyo Co., Ltd.

12.7. Takeda Pharmaceutical Company Limited

12.8. CSL Limited

12.9. Emergent BioSolutions Inc.

12.10. AstraZeneca

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900